– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 2024, we execu ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and t ...

Investors in Collegium Pharmaceutical, Inc. (COLL) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $20 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Gree ...

Q3'24 Earnings Report ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ November 7, 2024 | Nasdaq: COLL Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to ident ...

Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $1.34 a year ago.The reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $159.99 million. With the consensus EPS estimate being $1.66, the EPS surprise was -3.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.01%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.56 per share when it actually produced earnings of $1.62, delivering a surprise of 3.85%.Over the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (Sta ...

Exhibit 99.1 Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca Revenue of $53.2 Million and Record Xtampza ER Revenue of $49.5 Million – – Achieved Q3'24 GAAP Net Income of $9.3 Million – – Delivered Record Q3'24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) – – Appointed Vikram Karnani as Ch ...

Collegium Pharmaceutical (COLL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a c ...